SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending amid discussions around its partnerships and potential growth in the cybersecurity and IoT sectors, particularly regarding QNX technology. Community members are analyzing technical charts and expressing conviction about the company's long-term prospects, while also pointing to potential manipulation in share price movements. There's optimism related to partnerships with companies like NVIDIA and Microsoft.

What is the project about?  Swisscheese is a groundbreaking blockchain-based platform designed to empower individual investors and promote a completely decentralized financial ecosystem.  What makes your project unique?  Swisscheese's fundamental principle is to democratize investment opportunities by providing a user-driven platform where anybody can buy, sell, swap, pool, stake, and borrow digital assets, particularly traditional stocks represented in the digital world and our native token, SWCH.  History of your project.  It seeks to close the gap between established stock markets and the emerging cryptocurrency industry by building a strong environment where both worlds can communicate without friction.  What’s next for your project?  The Swisscheese platform provides a straightforward, effective, and transparent investing experience, regardless of whether you are an experienced user or a novice exploring the world of digital assets.  What can your token be used for?  Swisscheese is more than just a financial platform, it is the physical act of a desire to bring a new era of financial independence.

SwissCheese

SwissCheese ($SWCH) is trending amid discussions of a potential breakout, with bulls showing strong momentum. Community members are speculating about its potential as a decentralized platform, drawing comparisons to Solana.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The SLAP crypto community is buzzing with excitement, emphasizing their dedication and constant 'grind.' Discussions revolve around real-world partnerships, including sponsorships with pro athletes like Karolina Arm, generating bullish sentiment. Community members highlight the strong team and the project's potential for significant growth.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors digest Q3 earnings and a record cash pile, with debate focusing on Warren Buffett's cautious stance and the lack of share buybacks. The community is actively discussing the implications of the massive cash reserves amid potential market overvaluation and the company's next strategic moves. Some traders express frustration with the stock's recent performance compared to high-growth tech stocks.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors digest Q3 earnings, which revealed a record cash pile driven by cautious equity sales and a surge in operating profits fueled by insurance gains. Community discussions revolve around the implications of Warren Buffett's net selling of stocks and paused buybacks, with some speculating about potential acquisitions or a shift in investment strategy.  The surge in cash and lack of buybacks has fueled speculation, with community members joking about Warren Buffet's health and whether or not a market correction is imminent.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential for decentralized applications and AI integration, particularly with the upcoming launch of Caffeine.AI.  Conversations revolve around whether ICP can break through resistance levels and deliver on its promise, contrasting it with other Layer 1 solutions.  Despite some skepticism and past performance concerns, supporters highlight its innovative technology and growing ecosystem.

Roundhill ETF Trust - Roundhill Magnificent Seven Covered Call ETF

Roundhill Magnificent Seven Covered Call ETF

Roundhill Magnificent Seven Covered Call ETF ($MAGY) is trending as investors discuss its weekly dividend payouts and compare it to similar funds. Community members are evaluating its stability and potential for NAV erosion, particularly in comparison to other high-yield options. The ETF's consistent payouts and the possibility of generating daily income through a combination of different ETFs are also key discussion points.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates potential price movement, with some eyeing a "golden cross" and a test of the $100 mark. Discussions revolve around Litecoin potentially outperforming other cryptocurrencies like Zcash and whether an alt season is on the horizon. The recent launch of a Litecoin ETF and its potential impact are also being debated.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

LI is trending amidst discussions about its market position within the competitive Chinese EV sector and upcoming earnings, with community members weighing in on delivery numbers, new models like the i6, and potential impact from competitors like NIO. Some express concern over sales figures and market share, while others highlight the company's financial stability and expansion plans. Option activity and analyst ratings are also being closely monitored for potential catalysts.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

GLUE is trending as investors discuss the company's strong technical indicators and upcoming catalysts, including Phase 2b results and updates on the Novartis collaboration. Community members are pointing to the stock's potential for a significant squeeze due to high short interest and expressing excitement about its long-term prospects. The discussions also mention the broader context of molecular glue therapeutics and potential buyout scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months, the company said.&nbsp;</li><li>BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. &nbsp;</li></ul>BridgeBio Pharma, Inc. (BBIO) on Monday announced that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) is a rare, inherited disorder leading to progressive weakness and wasting of the arm and leg muscles, commonly later accompanied by pulmonary muscle and cardiac muscle involvement. It is caused by mutations in the FKRP gene, impairing glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells.<h2 class="st-heading-2">Other Trial Observations</h2>BridgeBio<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174417/0/en/BridgeBio-Reports-Positive-Phase-3-Results-for-Small-Molecule-BBP-418-in-LGMD2I-R9-FORTIFY-Study.html"> said</a> that glycosylated αDG increased by 1.8x from baseline at 3 months, whereas the placebo group showed little change. These improvements were sustained at 12 months in BBP-418-treated individuals, it further added.Furthermore, an average reduction of 82% from baseline in serum creatine kinase, a marker of muscle damage, was observed in BBP-418-treated individuals, it added.<h2 class="st-heading-2">Drug Safety</h2>BBP-418 was well-tolerated in the study with no new or unexpected safety findings observed, the company said. Overall, interim analysis data are supportive of a favorable risk-benefit profile for BBP-418, the company said.The company now intends to file a new drug application for approval of the therapy in the first half of 2026. It plans to engage with the U.S. Food and Drug Administration to discuss data from its studies later this year.<a href="https://stocktwits.com/symbol/BBIO">BBIO shares</a> traded 9% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around BBIO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.BBIO stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/neumora-therapeutics-experimental-drug-demonstrates-weight-loss-in-preclinical-studies/cLG030zR3ML">Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial

BridgeBio (BBIO) now intends to file a new drug application for the therapy's approval in the first half of 2026.

Equity

<ul class="summary-bullets"><li>Retail sentiment on Krispy Kreme stock jumped to ‘extremely bullish’ territory from ‘bearish’ compared to a day ago on Stocktwits.</li><li>Morgan Stanley kept its ‘Underweight’ rating on the stock with a $2.5 price.</li><li>Krispy Kreme was the top-performing stock, despite a broader slowdown in overall sector trends, Morgan Stanley said.</li></ul>Krispy Kreme (DNUT) stock traded above the 200-day moving average (DMA) for the first time since November 2024 and experienced an over 8,200% increase in retail user message count over 24 hours on Stocktwits, as of Wednesday morning, following a Morgan Stanley note that it was the top-performing restaurant stock in the third quarter.The stock touched a high of $5.11 on Wednesday versus the 200-DMA level of $4.66 earlier in the day. However, it had pared some of the gains as of the time of writing.Retail sentiment on Krispy Kreme jumped to ‘extremely bullish’ territory from ‘bearish’ compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Analyst Take On DNUT</h2>Morgan Stanley kept its ‘Underweight’ rating and a $2.5 price target on Krispy Kreme, according to MT Newswires. The firm noted that Krispy Kreme was the top-performing stock, despite a broader slowdown in overall sector trends.“Restaurants as a whole have performed poorly as industry data show a slowdown beginning in September,” Morgan Stanley said.<a href="https://stocktwits.com/symbol/DNUT">Shares of Krispy Kreme</a> have lost over 60% of their value in the last 12 months.<h2 class="st-heading-2">Recent Developments At Krispy Kreme</h2>Last week, Krispy Kreme announced the opening of its first store in Madrid, Spain, on October 2, 2025, through a minority interest joint venture with Glaseados Originales S.L. The company said that additional shop openings in Brazil and Uzbekistan are planned before the end of 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/beyond-meat-stock-skyrockets-60-today-meme-stock-frenzy-intensifies-after-etf-inclusion-amid-surging-retail-buzz/cLG5aNdR3qg">Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz</a>

The Krispy Kreme corporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

DNUT Stock Trades Above 200-DMA For The First Time Since November 2024

Morgan Stanley kept its ‘Underweight’ rating and $2.5 price target on Krispy Kreme.

<ul class="summary-bullets"><li>Beyond Meat stock experienced a 200% increase in retail user messages on Stocktwits.</li><li>Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF.</li><li>Retail sentiment on Beyond Meat remained unchanged in the ‘extremely high’ territory.</li></ul>Beyond Meat (BYND) saw a nearly 200% surge in retail user messages on Stocktwits over the last 24 hours, with its shares jumping over 60% in early trading on Wednesday, mirroring a meme-stock rally following its addition to the Roundhill Meme Stock ETF (MEME).Retail sentiment on <a href="https://stocktwits.com/symbol/BYND">Beyond Meat</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Retail Users’ Take On The Stock Surge</h2>A bullish user on Stocktwits noted that the stock could surpass the $10 mark.<stembedurl>https://stocktwits.com/MarketWhispererr/message/633216899</stembedurl>Another user said that Beyond Meat was mirroring GameStop.<stembedurl>https://stocktwits.com/InvestingCat/message/633216438</stembedurl><h2 class="st-heading-2">Stock Milestones</h2>Beyond Meat’s stock has surged over 1,300% from Thursday’s closing price of $0.52. The stock has been gaining every day since then and hit a high of $7.69 in Wednesday’s trading.Last week, the company announced the early settlement of its previously announced exchange offer for convertible senior notes due 2027.Analysts have noted that the firm’s growth has been impacted by increased competition, adverse shifts in consumer perceptions of the health attributes of Beyond Meat products, and termination fees from co-manufacturers.Shares of Beyond Meat have gained over 43% this year but have declined nearly 13% in the last months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/applied-digital-stock-soars-7-premarket-on-5-b-ai-factory-lease/cLG5JkyR3q7">Applied Digital Stock Soars 7% Pre-Market On $5B AI Factory Lease With US Hyperscaler</a>

A group of bondholders of Beyond Meat are reportedly working with the company’s law firm for a possible restructuring.

Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz

Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF.

Praxis Precision Medicines, Inc. (PRAX) announced on Thursday that patients with essential tremor treated with Ulixacaltamide in a late-stage study showed improvement in functional independence.A 4.3 point mean improvement in the Modified Activities of Daily Living 11 (mADL11) score was observed at week 8 in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1">said</a>. The score is used to assess a person's functional independence and evaluate a person’s ability to do day-to-day activities. Furthermore, the effect was sustained from week 2 throughout the 12-week dosing period, it added.Essential Tremor is the most common movement disorder, affecting roughly seven million people in the U.S. alone, according to Praxis. It is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs.Praxis now plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026. Shares of the company rallied 76% in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory, while message volume increased from ‘low’ to ‘extremely high’ levels.The company said that Ulixacaltamide was generally well-tolerated over 12 weeks of treatment, and no deaths or drug-related serious adverse events were recorded. However, discontinuations in the study were 35.6% in patients who received Ulixacaltamide as compared to 5.6% in patients who received placebo, and most discontinuations were primarily due to treatment-emergent adverse events, it said.The company also conducted another late-stage trial where patients showed superior maintenance of effect while on Ulixacaltamide versus placebo after blinded exposure for 8 weeks with Ulixacaltamide.PRAX stock is down by 25% this year and by about 23% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

SELLAS Life Sciences Group (SLS) announced on Monday that preclinical data support its SLS009 as a monotherapy or in combination with Venetoclax for treating a rare and highly aggressive form of mature T-cell leukemia.The biopharmaceutical company said that data supporting the drug in T-cell prolymphocytic leukemia will be presented at the European Society for Medical Oncology Congress 2025, being held October 17 to October 21, in Berlin, Germany. T-PLL or T-cell prolymphocytic leukemia is a rare, aggressive type of mature T-cell leukemia that primarily affects older adults, characterized by the rapid growth of cancerous T-cells.SELLAS <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-to-Present-In-Vivo-Preclinical-Data-Demonstrating-Statistically-Significant-Survival-Benefit-of-SLS009-in-T-Cell-Prolymphocytic-Leukemia-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2025/default.aspx">said</a> that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. The combination regimen, which prolonged overall survival to 7.9 weeks, was also well tolerated in the study, the company said.Chief Development Officer at SELLAS, Dragan Cicic, said that the results from the study are “highly encouraging” and noted that T-PLL has minimal treatment options.SLS shares traded 5% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> remained in the ‘bullish’ territory, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_11_30_56_AM_png_b0f4827381.webp" alt="SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="622" height="61"><figcaption>SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user wondered why the stock didn’t rally further on the news.<stembedurl>https://stocktwits.com/SunnySeed/message/632108231</stembedurl>SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.SLS stock has nearly doubled this year and is up about 60% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-rally-in-ndra-stock-today/ch6Sk9VR3kY">What’s Driving The Rally In NDRA Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

A White House official reportedly stated on Monday that the Trump administration was not evaluating a deal to acquire a stake in Critical Metals Corp (CRML) following a Reuters report that the government was considering such a move, which sparked a surge in the rare earths company's stock.Shares of Critical Metals still traded over 46% higher in afternoon trading on Monday. According to a Bloomberg News report, a White House official stated that the administration was in regular contact with the private sector and had received hundreds of deal proposals involving equity stakes.The report added that no active discussions were underway regarding a deal with Critical Metals, which is involved in Greenland’s largest rare earths project. The Reuters report noted that the U.S. was aiming to secure access to Greenland’s Tanbreez project, which Critical Metals acquired last year for $5 million in cash and $211 million in stock.Retail sentiment on <a href="https://stocktwits.com/symbol/CRML">Critical Metals</a> remained unchanged in the ‘extremely bullish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Bloomberg reported that U.S. President Donald Trump has unveiled several agreements in recent months, in which companies have traded equity stakes in return for access to government loans and subsidies. The report added that last month, the U.S. took a 5% stake in Lithium Americas and announced the Vancouver-based company could draw on a previously agreed-upon $2.23 billion loan. In August, Intel Corp announced that the U.S. government would take a 9.9% stake in the firm for $8.9 billion.Critical Metal shares have gained nearly 75% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dollar-tree-shares-dip-after-bernstein-cuts-price-target/ch6RJjIR3g8">Dollar Tree Shares Dip After Bernstein Cuts Price Target On EBIT Performance</a>

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. (Photo by Win McNamee/Getty Images)

White House Reportedly Denies Plans To Acquire Stake In Critical Metals

According to a Bloomberg News report, there were no active discussions underway regarding a deal with Critical Metals, which is involved in Greenland’s largest rare earths project.

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Vanguard Group, Inc. - Vanguard Russell 2000 Growth Index ETF

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$241.41
Prev Close	$239.17
Open	$240.25
Dividend Yield	N/A
50-Day Moving Average	$233.76
Beta	N/A
Avg. Volume	16,199.86
PE Ratio	N/A

52-Week High	$246.00
52-Week Low	$160.03
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF